# INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi

> **NCT04945070** · PHASE4 · UNKNOWN · sponsor: **Institute for Clinical and Experimental Medicine** · enrollment: 96 (estimated)

## Conditions studied

- Type 2 Diabetes Treated With Insulin

## Interventions

- **DRUG:** IGlarLixi
- **DRUG:** MDI - Multiple dose insulin injection

## Key facts

- **NCT ID:** NCT04945070
- **Lead sponsor:** Institute for Clinical and Experimental Medicine
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07
- **Primary completion:** 2023-01
- **Final completion:** 2023-06
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2021-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04945070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04945070, "INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04945070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*